

Bhausahab Bagal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2276559/publications.pdf>

Version: 2024-02-01

98
papers

517
citations

840585

11
h-index

839398

18
g-index

100
all docs

100
docs citations

100
times ranked

784
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of cytogenetic response in CML patients with variant Philadelphia translocation. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 99-108.	0.7	2
2	Iatrogenic Immunodeficiency Associated Lymphoproliferative Disorder in Patients with Acute Lymphoblastic Leukemia: A Case Series. Indian Journal of Hematology and Blood Transfusion, 2022, 38, 194-195.	0.3	0
3	Systemic inflammatory biomarkers in primary central nervous system lymphoma versus high-grade glioma: exploratory, comparative and correlative analysis. CNS Oncology, 2022, 11, CNS83.	1.2	3
4	Role of Curcumin in Reducing Toxicities Associated With Mucosal Injury Following Melphalan-Based Conditioning in Autologous Transplant Setting. Cell Transplantation, 2022, 31, 096368972210869.	1.2	2
5	Hodgkin Lymphoma in Adolescent and Young Adults: Real-World Data from a Single Tertiary Cancer Center in India. Journal of Adolescent and Young Adult Oncology, 2021, 10, 581-587.	0.7	2
6	Systematic Review of the Burden and Treatment Patterns of Adult and Adolescent Acute Lymphoblastic Leukemia in India: Comprehending the Challenges in an Emerging Economy. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e85-e98.	0.2	5
7	OUP accepted manuscript. Neuro-Oncology, 2021, 23, 2117-2118.	0.6	0
8	Pre-transplant use of tyrosine kinase inhibitors and transplant associated thrombotic microangiopathy - a single centre analysis of incidence, risk factors and outcomes. Bone Marrow Transplantation, 2021, 56, 1558-1562.	1.3	3
9	Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol. Blood Advances, 2021, 5, 1178-1193.	2.5	19
10	Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML). Leukemia, 2021, 35, 1392-1404.	3.3	51
11	Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INWARD) of the Hematology Cancer Consortium (HCC). British Journal of Haematology, 2021, 193, e1-e4.	1.2	9
12	Outcomes of Patients with Primary Mediastinal B-Cell Lymphoma Treated with Dose Adjusted R-EPOCH Regimen: A Single Centre Experience. Indian Journal of Hematology and Blood Transfusion, 2021, 37, 379-385.	0.3	2
13	Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma—Experience From a Tertiary Care Cancer Center. JCO Global Oncology, 2021, 7, 361-367.	0.8	8
14	Subcutaneous Panniculitis-Like T-Cell Lymphoma: Clinical Features and Outcomes from a Single Tertiary Center. Indian Journal of Hematology and Blood Transfusion, 2021, 37, 697-698.	0.3	2
15	Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia. Blood Advances, 2021, 5, 3436-3444.	2.5	6
16	Expression of CD304/neuropilin-1 in adult B-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment. International Journal of Laboratory Hematology, 2021, 43, 990-999.	0.7	4
17	Role of cytogenetic abnormalities detected by fluorescence hybridization as a prognostic marker: Pathogenesis & clinical course in patients with B-chronic lymphocytic leukaemia. Indian Journal of Medical Research, 2021, 153, 475-483.	0.4	0
18	Evaluating the Clinical Utility of Staged Bronchoalveolar Lavage (BAL) Fluid Analysis in Adolescent and Adult Acute Leukemia and Lymphoma Patients with Febrile Neutropenia and Lung Infiltrates. Blood, 2021, 138, 4008-4008.	0.6	0

#	ARTICLE	IF	CITATIONS
19	A Prospective Survey to Understand the Preferences and Perspectives of Patients with Hematological Malignancies in a Tertiary Cancer Care Setting in India (CANCOV SURVEY). <i>Blood</i> , 2021, 138, 837-837.	0.6	0
20	Role of cytogenetic abnormalities detected by fluorescence in situ hybridization as a prognostic marker: Pathogenesis & clinical course in patients with B-chronic lymphocytic leukaemia. <i>Indian Journal of Medical Research</i> , 2021, 153, 475.	0.4	1
21	Multicentric Castleman's disease in India - Does EBV rather than HHV8 play a role?. <i>Indian Journal of Pathology and Microbiology</i> , 2021, 64, 302-309.	0.1	0
22	Investigating the clinical, hematological and cytogenetic profile of endoreduplicated hypodiploids in BCP-ALL. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 85, 102465.	0.6	2
23	NARASIMHA: Novel Assay based on Targeted RNA Sequencing to Identify ChiMeric Gene Fusions in Hematological Malignancies. <i>Blood Cancer Journal</i> , 2020, 10, 50.	2.8	9
24	Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center. <i>JCO Global Oncology</i> , 2020, 6, 1684-1695.	0.8	11
25	Primary diffuse large B cell lymphoma of Uterine Cervix: Treatment outcomes of a rare entity with literature review. <i>Cancer Reports</i> , 2020, 3, e1264.	0.6	12
26	Machine learning derived genomics driven prognostication for acute myeloid leukemia with <i>RUNX1-RUNX1T1</i> . <i>Leukemia and Lymphoma</i> , 2020, 61, 3154-3160.	0.6	8
27	Bortezomib and cyclophosphamide based chemo-mobilization in multiple myeloma. <i>International Journal of Hematology</i> , 2020, 112, 835-840.	0.7	3
28	Over expression of brain and acute leukemia, cytoplasmic and ETS-related gene is associated with poor outcome in acute myeloid leukemia. <i>Hematological Oncology</i> , 2020, 38, 808-816.	0.8	1
29	COVID-19 in cancer patients on active systemic therapy – Outcomes from LMIC scenario with an emphasis on need for active treatment. <i>Cancer Medicine</i> , 2020, 9, 8747-8753.	1.3	29
30	A Limited Sampling Strategy for Therapeutic Drug Monitoring of Mycophenolate Mofetil for Prophylaxis of Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation. <i>Cell Transplantation</i> , 2020, 29, 096368972091292.	1.2	2
31	A rare case of aggressive, Merkel Cell Carcinoma of the male breast co-existing with chronic lymphocytic leukemia. <i>Breast Journal</i> , 2020, 26, 1389-1391.	0.4	1
32	Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy. <i>Medical Oncology</i> , 2020, 37, 48.	1.2	1
33	Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy. , 2020, 8, e000630.		30
34	The Th9 Axis Reduces the Oxidative Stress and Promotes the Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma Patients. <i>Molecular Cancer Research</i> , 2020, 18, 657-668.	1.5	17
35	COVID-19 in hematological malignancies. <i>Cancer Research Statistics and Treatment</i> , 2020, 3, 345.	0.1	2
36	Daratumumab and its efficacy in refractory myeloma with anemia. <i>Cancer Research Statistics and Treatment</i> , 2020, 3, 832.	0.1	3

#	ARTICLE	IF	CITATIONS
37	Twin trouble. <i>Cancer Research Statistics and Treatment</i> , 2020, 3, 307.	0.1	0
38	Comparison of Outcomes of Donor Lymphocyte Infusions with or without Lenalidomide in Patients with Hematological Malignancies Post Allogeneic Transplant. <i>Blood</i> , 2020, 136, 28-29.	0.6	0
39	Real World Experience of Etanercept in Steroid Refractory Acute Graft Versus Host Disease from a Tertiary Cancer Centre in India. <i>Blood</i> , 2020, 136, 2-3.	0.6	0
40	Incidence, Risk Factors, and Outcomes of Viral Reactivations in Alternative Donor Haematopoietic Stem Cell Transplant. <i>Blood</i> , 2020, 136, 24-25.	0.6	0
41	Molecular Measurable Residual Disease Detection in Acute Myeloid Leukemia Using Error Corrected Next Generation Sequencing. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
42	A phase III randomized controlled trial of radiation dose optimization in non-Hodgkin lymphoma diffuse large B-cell lymphoma (DOBL study): Study protocol and design. <i>Cancer Reports</i> , 2019, 2, e1161.	0.6	1
43	Real World Data on Efficacy and Safety of ABVD Regimen in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL): Retrospective Analysis from Tertiary Care Cancer Centre. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S308.	0.2	0
44	Efficacy of Pediatric Inspired Modified BFM 90 Protocol in Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Retrospective Analysis from Tertiary Care Cancer Centre. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S198.	0.2	0
45	Outcomes with Chemoimmunotherapy in Angioimmunoblastic T Cell Lymphoma - Experience from a Single Tertiary Care Centre. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S361-S362.	0.2	0
46	A novel machine-learning-derived genetic score correlates with measurable residual disease and is highly predictive of outcome in acute myeloid leukemia with mutated NPM1. <i>Blood Cancer Journal</i> , 2019, 9, 79.	2.8	13
47	Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context. <i>Frontiers in Oncology</i> , 2019, 9, 450.	1.3	14
48	Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia in Era of Tyrosine Kinase Inhibitors -a Single Centre Experience from India. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S103.	2.0	1
49	Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma. <i>CNS Oncology</i> , 2019, 8, CNS46.	1.2	18
50	Standardization of High Sensitivity Minimal Residual Disease Monitoring in Multiple Myeloma: An Experience in Tertiary Cancer Centre. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e183.	0.2	0
51	Evaluation of CD319 (SLAMF7) as a Novel Gating Marker for Plasma Cells in Flow Cytometric Immunophenotyping of Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e153.	0.2	0
52	Standardization of High Sensitivity Minimal Residual Disease Monitoring in Multiple Myeloma: An Experience in Tertiary Cancer Centre. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e357.	0.2	1
53	A Comprehensive Serum MicroRNA Profiling in Indian Multiple Myeloma Patients Uniformly Treated With VCD-Protocol. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e80.	0.2	0
54	Prognostic Relevance of the Proportion of Residual Polyclonal Plasma Cells in the Diagnostic Bone Marrow of Newly Diagnosed Multiple Myeloma Patients Managed Without Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e238-e239.	0.2	0

#	ARTICLE	IF	CITATIONS
55	Pre-Transplant Use of Tyrosine Kinase Inhibitors Increases Risk of Transplant Associated Thrombotic Microangiopathy - a Single Centre Analysis of Incidence, Risk Factors and Outcomes. <i>Blood</i> , 2019, 134, 1983-1983.	0.6	2
56	Outcomes in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL): A Report from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC). <i>Blood</i> , 2019, 134, 1306-1306.	0.6	6
57	Fludarabine Melphalan Versus Fludarabine Treosulfan As Reduced Intensity Conditioning Regimens in Allogeneic Hematopoietic Stem Cell Transplant - a Retrospective Analysis. <i>Blood</i> , 2019, 134, 4493-4493.	0.6	2
58	A Phase II Non-Randomized Study to Evaluate the Efficacy of Single Dose Rasburicase (1.5mg) in Adult Acute Leukemia and High Grade Lymphomas with Established Tumor Lysis Syndrome. <i>Blood</i> , 2019, 134, 2914-2914.	0.6	1
59	Induction therapy in newly diagnosed multiple myeloma: Current research scenario and questions for the future. <i>Cancer Research Statistics and Treatment</i> , 2019, 2, 76.	0.1	12
60	Clinical radiological features of methotrexate-induced subacute leukoencephalopathy in patients with acute lymphoblastic leukemia: 'Panda eye sign' on diffusion weighted-magnetic resonance imaging. <i>Cancer Research Statistics and Treatment</i> , 2019, 2, 28.	0.1	4
61	Author reply to - Jain H. et al. and Tandon N. et al.. <i>Cancer Research Statistics and Treatment</i> , 2019, 2, 272.	0.1	0
62	Single Arm, Single Centre Prospective Study to Assess the Effect of Therapeutic Drug Monitoring (TDM) Based Dosage Adjustment of Posaconazole on the Incidence of Invasive Fungal Infections (IFIs) in AML Patients on Induction Chemotherapy on Posaconazole Prophylaxis. <i>Blood</i> , 2019, 134, 2600-2600.	0.6	0
63	A Novel Machine Learning Derived Genomics-Based Scoring System Is Highly Predictive of Outcome in Core Binding Factor Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2710-2710.	0.6	0
64	Low, fixed dose defibrotide in management of hepatic veno-occlusive disease post stem cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 47-51.	0.6	6
65	Successful Treatment of Transplant Associated Thrombotic Microangiopathy (TA-TMA) with Low Dose Defibrotide. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2018, 34, 469-473.	0.3	16
66	Outcomes of Patients with Splenic Marginal Zone Lymphoma Treated with Rituximab or Splenectomy: Report from Tertiary Cancer Center in India. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S282-S283.	0.2	0
67	Splenic marginal zone lymphoma relapsing as miliary lung mottling: an unusual presentation. <i>Blood Research</i> , 2018, 53, 103.	0.5	0
68	Hematological Cancer Consortium: Multi-Center Acute Myeloid Leukemia Registry Data from India. <i>Blood</i> , 2018, 132, 4006-4006.	0.6	4
69	Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in <i><i>NPM1</i></i> mutated acute myeloid leukemia. <i>Oncotarget</i> , 2018, 9, 36613-36624.	0.8	26
70	Lomustine, cytarabine, cyclophosphamide, etoposide – An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 926.	0.3	9
71	Long term clinical outcomes of adult hematolymphoid malignancies treated at Tata Memorial Hospital: An institutional audit. <i>Indian Journal of Cancer</i> , 2018, 55, 9.	0.2	9
72	BRAFV600E mutation in hairy cell leukemia: A single-center experience. <i>Indian Journal of Pathology and Microbiology</i> , 2018, 61, 532.	0.1	2

#	ARTICLE	IF	CITATIONS
73	Bortezomib in Combination with Cyclophosphamide and G-CSF for Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma. <i>Blood</i> , 2018, 132, 2067-2067.	0.6	1
74	Hematological Cancer Consortium: Multi-Center Acute Lymphoblastic Leukemia Registry Data from India. <i>Blood</i> , 2018, 132, 1374-1374.	0.6	0
75	Immunophenotypic Assessment of Minimal Residual Disease in Younger Acute Myeloid Leukemia Patients Is Highly Predictive of Outcome. <i>Blood</i> , 2018, 132, 1498-1498.	0.6	0
76	Role of Multicolor Flow Cytometry in Assessing Bone Marrow Involvement by Solitary Plasmacytoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e25.	0.2	0
77	High Dose Chemotherapy with Autologous Stem Cell Transplantation for Multiple Myeloma: Outcomes at Tata Memorial Centre. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e126.	0.2	5
78	A Retrospective Cohort Study to Evaluate the Outcomes of Multiple Myeloma Treated in a Tertiary Care Centre from India. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e92.	0.2	1
79	Study of stem cell homing & self-renewal marker gene profile of ex vivo expanded human CD34 ⁺ cells manipulated with a mixture of cytokines & stromal cell-derived factor 1. <i>Indian Journal of Medical Research</i> , 2017, 146, 56.	0.4	3
80	Immunogenetics of chronic lymphocytic leukemia. <i>Indian Journal of Pathology and Microbiology</i> , 2017, 60, 38-42.	0.1	5
81	Hepatitis B-related serological events in hematopoietic stem cell transplant patients and efficacy of lamivudine prophylaxis against reactivation. <i>Hematological Oncology</i> , 2016, 34, 140-146.	0.8	8
82	Chronic Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: Analysis of Risk Factors, Pattern and Long Term Outcome. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016, 32, 32-38.	0.3	9
83	Characteristics of <i>BCR-ABL</i> kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance. <i>Leukemia and Lymphoma</i> , 2016, 57, 2653-2660.	0.6	13
84	Ascites as a Manifestation of GVHD: a Rare Phenomenon. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016, 32, 189-191.	0.3	4
85	Plasmacytoid Dendritic Cell Levels at End of Induction Are Predictive of MRD Clearance and Also Influence Disease Outcome in a Subset of Patients. <i>Blood</i> , 2016, 128, 5263-5263.	0.6	0
86	Minimal Residual Disease in Acute Myeloid Leukemia Using a Difference from Normal Approach Is Predictive of Outcome. <i>Blood</i> , 2016, 128, 5249-5249.	0.6	0
87	A Retrospective Cohort Study to Evaluate the Outcomes of HIV-Associated High-Grade B-Cell Non-Hodgkin Lymphoma (NHL) Treated with Dose Adjusted R EPOCH Regimen. <i>Blood</i> , 2016, 128, 4213-4213.	0.6	1
88	Risk Factors, Pattern and Clinical Outcome of Acute Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplant. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2015, 31, 404-412.	0.3	7
89	<i>MYD88</i> mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart. <i>Leukemia and Lymphoma</i> , 2015, 56, 420-425.	0.6	16
90	Improved Outcomes with Allogeneic Stem Cell Transplantation for Aplastic Anaemia Using HLA Identical Sibling Donors: The Indian Stem Cell Transplant Registry (ISCTR) Experience. <i>Blood</i> , 2015, 126, 4386-4386.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Low Dose Defibrotide for Management of Hepatic Veno-Occlusive Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S190-S191.	2.0	0
92	Pretransplant PET Positivity Predicts Early Relapse with Poor Outcome in Patients of Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 3997-3997.	0.6	1
93	Minimal Residual Disease by Multiparametric Flow Cytometry Predicts Relapse Free Survival better than Over-Expression of WT1 and BAALC in Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 1064-1064.	0.6	0
94	Increased Incidence of Symptomatic Hyponatremia with Voriconazole Prophylaxis during Cyclophosphamide Based Conditioning in Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 2467-2467.	0.6	2
95	LACE - an Effective Conditioning Regimen for Lymphoma Patients Undergoing Autologous Transplant- Analysis of Outcomes and Prognostic Factors. <i>Blood</i> , 2014, 124, 3979-3979.	0.6	0
96	Comparison of the efficacy and safety of Rituximab (Mabthera [®] , Φ) and its biosimilar (Reditux [®] , Φ) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2013, 34, 292.	0.1	41
97	MYD88 Negative Waldenstrom Macroglobulinemia Has Distinct Clinical & Biological Features As Compared To Its MYD88 Mutant Counterpart. <i>Blood</i> , 2013, 122, 4299-4299.	0.6	2
98	Hepatitis B Related Serological Events In Hematopoietic Stem Cell Transplant Patients and Efficacy Of Lamivudine Prophylaxis Against Reactivation. <i>Blood</i> , 2013, 122, 2043-2043.	0.6	0